Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
Murdoch Childrens Research Institute
London School of Hygiene and Tropical Medicine

      This is an open-label prospective community intervention trial to assess the impact of
      community mass treatment with azithromycin for yaws and ivermectin for scabies, on non-yaws
      bacterial skin infections.

      Communities will be randomised to receive standard treatment for both yaws and scabies either
      in parallel (site 1) or in sequence (site 2).

      Treatment of yaws:

      Single dose of Azithromycin (30mg/kg, max 2G).

      Treatment of scabies:

      Either an oral dose of Ivermectin (200μg/kg) or permethrin cream for those with a
      contraindication to Ivermectin (WT<15kg, pregnant or breastfeeding women) given in 2 doses
      7-14 days apart.

      Investigators will complete a clinical and microbiological assessment of bacterial skin
      disease at baseline and at 12 months to assess the impact of treatment on the prevalence of
      bacterial infection and the emergence of antimicrobial resistance.

      Primary Outcome

        1. Difference in the change in prevalence of impetigo between baseline and 12- months
           between the parallel and the sequential treatment arms.

           Secondary Outcomes

        2. Change in the proportion of swab samples from which S. pyogenes is cultured between
           baseline and follow-up in the two arms

        3. The proportion of samples from which a drug-resistant isolate of S.pyogenes is cultured
           in the two arms
    
Drug